Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
Plummer ER. et al, (2005), Clin Cancer Res, 11, 3402 - 3409
Phase 1 dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT): First report.
Benghiat A. et al, (2004), JOURNAL OF CLINICAL ONCOLOGY, 22, 149S - 149S
Phase 1 dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT): First report.
Benghiat A. et al, (2004), J Clin Oncol, 22
Preliminary experience using high-intensity focused ultrasound for the treatment of kidney and liver tumours
Illing RO. et al, (2004), BRITISH JOURNAL OF CANCER, 91, S21 - S21
Contrast-enhanced ultrasound assessment of tissue response to high-intensity focused ultrasound.
Kennedy JE. et al, (2004), Ultrasound Med Biol, 30, 851 - 854
DNA repair pathways in drug resistance in melanoma.
Bradbury PA. and Middleton MR., (2004), Anticancer Drugs, 15, 421 - 426
DNA repair pathways in drug resistance in melanoma
Bradbury PA. and Middleton MR., (2004), ANTI-CANCER DRUGS, 15, 421 - 426
High-intensity focused ultrasound for the treatment of liver tumours.
Kennedy JE. et al, (2004), Ultrasonics, 42, 931 - 935
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S. et al, (2003), J Clin Oncol, 21, 2551 - 2557
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Kiebert GM. et al, (2003), Cancer Invest, 21, 821 - 829
Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.
Middleton MR. and Margison GP., (2003), Lancet Oncol, 4, 37 - 44
Brain metastases in melanoma: a European perspective.
Cattell E. et al, (2002), Semin Oncol, 29, 513 - 517
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Middleton MR. et al, (2002), Int J Cancer, 100, 615 - 617
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.
Middleton M. et al, (2002), J Clin Pharmacol, 42, 774 - 781
Assessing outcomes in palliative chemotherapy.
Cattell E. et al, (2002), Expert Opin Pharmacother, 3, 693 - 700
Toxicity of temozolomide with response modifiers in metastatic malignant melanoma
Lorigan P. et al, (2002), BRITISH JOURNAL OF CANCER, 86, S68 - S68
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Paul MJ. et al, (2002), Melanoma Res, 12, 175 - 178